Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
- HIV / AIDs
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 252412
IPSCIO Record ID: 368651
This agreement includes a non-exclusive grant back from Licensee to Licensor.
The Compound is designated by Licensor as Resiquimod (R-848), S36212, 1-(4-aminobutoxy) -2-butyl-lH-imidazo (4,5-cl quinolin-4-amine and conjugates thereof.
Product shall mean any combination of a Licensee Antigen Presenting Cell or APC Targeting Technology vaccine with a Licensed Compound to be utilized as a Vaccine Adjuvant.
Vaccine Adjuvant shall mean a Licensed Compound which is used to induce, augment, fine-tune, enhance, or desensitize an antigen-specific immune response to an antigen contained in a vaccine or generated by a DNA vaccine for the therapeutic treatment of an existing disease or prophylactic use as protection against future disease, including desensitization to allergens. The antigen and the vaccine adjuvant may be admixed, delivered simultaneously, conjugated, or delivered separately, provided however, that the separate administration of the antigen and vaccine adjuvant is limited to the topical, dermal or mucosal or intradermal routes of administration and must be administered within 48 hours at substantially the same site and labeled as such by the applicable regulatory authority.
TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.
The Field shall mean human prophylactic or therapeutic vaccination against any and all cancer disease states and selected infectious diseases.
This agreement focus is Cancer and the Infectious Diseases
– human immunodeficiency virus (HIV);
– human papillomavirus (HPV); and,
– hepatitis B virus (HBV).
IPSCIO Record ID: 372620
Licensor grants an exclusive license under Licensor Patent Rights and Licensor Know-How with a right to sublicense, to make and have made the Licensed Vaccine and/or the Products in the Territory other than the United States, for any and all uses in the Territory in the Field.
Licensor grants a non-exclusive license under Licensor Patent Rights and Licensor Know-How with a right to sublicense, to make and have made the Licensed Vaccine and/or the Products in the United States, for any and all uses in the Territory in the Field.
For the Non-Exclusive License Grant, in the event that the making, having made, use, offer for sale, sale or import by Licensee, or its Related Parties, of Licensed Vaccine or Products would infringe during the term of this Agreement a claim of issued letters patent which Licensor owns and which patents are not covered by the grant, Licensor grants, to the extent Licensor is legally able to do so, a non-exclusive, sublicensable license in the Territory under such issued letters patent for Licensee and its Related Parties to develop, make, have made, use, sell, offer for sale or import Licensed Vaccines and Products in the Territory.
If Licensee desires to use any trademark identified by Licensor as of the Effective Date for use for the Licensed Vaccine and/or Product in the Territory, it will include without limitation the trademark Heplisavâ„¢.
Hepatitis B Surface Antigen shall mean an immunogenically effective Hepatitis B Surface Antigen protein that is produced by recombinant DNA technology.
x-ISS shall mean the adjuvant, an immunostimulatory sequence (ISS) composed of the 22mer phosphorothioate oligonucleotide sequence 5 TGA CTG TGA ACG TIC GAG ATG A3.
Patents and know-how include
ISSs, Compositions and Methods of Use;
DNA Molecules Coding for FMDH Control Regions; and,
Immunostimulatory Nucleic Acid Molecules.
The trademark is Heplisavâ„¢.
Heplisav-B is a vaccine used in adults 18 and over to prevent hepatitis B, a viral infection of the liver.
IPSCIO Record ID: 212650
â€œLicensed Productâ€ shall mean a prophylactic vaccine containing the Compound co-formulated with the Antigen for delivery by the Delivery Method. No Licensed Product(s) may be developed for the prevention, treatment or control of any cancer nor may any clinical trial be conducted with clinical endpoints of prevention, treatment or control of any cancer.
Patents Claiming Priority to Patent Application Serial No. 08/276,358
IPSCIO Record ID: 279292
For the Trademarks for Licensed Products. To the extent that Licensor owns any Trademark(s) that pertain specifically to a Licensed Vaccine or Licensed Product, Licensor grants an exclusive right and license, with the right to grant sublicenses to Trademark(s) Controlled by Licensor solely for use with respect to such Licensed Vaccine or Licensed Product, as the case may be.
Licensor has rights under certain patent rights and know-how rights relating to Tarmogens.
Licensed Product means any product in final form that contains a Licensed Vaccine as a therapeutically or prophylactically active ingredient.
Combination Product means any product sold in a particular country that contains a Licensed Vaccine in combination with one (1) or more other therapeutically active ingredients or drug delivery technology, devices, equipment or other components, as applicable, or formulated or packaged separately but sold together for a single price.
The Field means, any and all human diseases and conditions, except the treatment of any malignancy; provided, however, that Field shall include [the treatment, palliation, diagnosis and/or prevention of hepatitis that may result in the prevention and/or reduction in frequency and incidence of any and all sequelae of hepatitis infection, including the prevention and/or reduction in the frequency and incidence of hepatocellular carcinoma in patients who have co-existing hepatocellular carcinoma.
IPSCIO Record ID: 257474
The parties wish to further amend the Agreement to provide that Merck shall have rights to vaccine products for the treatment of patients infected with Human Immunodeficiency Virus and Hepatitis B Virus.
IPSCIO Record ID: 52613
IPSCIO Record ID: 375114
Streptococcus pneumoniae is a bacteria that is a major cause of pneumonia. It can spread in persons carrying the bacteria in their upper respiratory tracts by direct person-to-person contact via respiratory droplets.